Durack, Juliana
Boushey, Homer A.
Lynch, Susan V.
Funding for this research was provided by:
National Institutes of Health
Article History
First Online: 8 July 2016
Compliance with Ethical Standards
:
: Dr. Lynch reports grants from NIH/NIAID, Janssen Inc., Broad Foundation, Sloan Foundation, Pfizer Inc., NIH/NICHD, NIH/NHLBI, and NIH/NIDDK. In addition, Dr. Lynch has a patent Stan449-PRV REDUCTIVE PRODRUG CANCER CHEMOTHERA issued, a patent Combination antibiotic and antibody therapy for the treatment of <i>Pseudomonas aeruginosa</i> infection with royalties paid, a patent Provisional filing for use of <i>Lactobacillus sakei</i> and other lactic acid bacteria as a therapeutic strategy for chronic rhinosinusitis issued, a patent Provisional filing for claims associated with use of PhyloChip as a diagnostic and prognostic clinical tool issued, and a patent Bacterial Therapeutic Consortium for induction of Immune Tolerance pending. Dr. Boushey reports grants from the National Heart, Lung, and Blood Institute and National Institute of Allergy and Infectious Diseases. Dr. Durack declares no conflicts of interest relevant to this manuscript.
: This article does not contain any studies with human or animal subjects performed by any of the authors.